Study reveals every bowel tumour and bowel cancer cell have unique genetic fingerprints
Single-cell technology and organoids enable researchers to study cancer-specific processes...
List view / Grid view
Single-cell technology and organoids enable researchers to study cancer-specific processes...
Researchers have bioengineered organs that are free from the risk of tumour growth--and of sufficient volume and size for viable transplant...
An international team of researchers have developed 3D cell cultures in which genes can be specifically modified to improve the use of targeted anti-cancer drugs...
Researchers have developed a method, based on CRISPR-Cas9 technology in organoids, to study the genetic cause of hereditary forms of cancer...
Engineers have demonstrated a technique for making 3-D-printed biomaterials that can degrade on demand, which can be useful in making intricately patterned microfluidic devices...
A miniature human heart, created by introducing human cells into the matrix of a whole rat heart, may make it easier to confirm basic science findings...
Degeneration of cartilage and other joint tissues is a major cause of disability.
'Mini organs' may aid in understanding and treating respiratory diseases.
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
A new method could push research into developmental brain disorders an important step forward.
Organ models, which are cultivated in the laboratory from human stem cells and grow into living tissue, are one of the most important scientific breakthroughs of recent years.
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
New synthetic 3D gel technology for cell culture promises to unlock the potential of ‘mini-organs’ for industrial drug discovery.
The biomaterials company QGel has received $12 million to be used to accelerate QGel’s global expansion and broaden the company "organoids" products.
15 July 2015 | By Victoria White
Galapagos has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for preclinical research in cystic fibrosis and IBD...